CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 2, 2018--
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical
company developing novel medicines to treat life-altering central
nervous system (CNS) disorders, today announced that the Company is
scheduled to present at the J.P. Morgan 2018 Healthcare Conference in
San Francisco on Tuesday, January 9, 2018 at 11:30 a.m. PT (2:30 p.m.
ET), followed by a Q&A session.
A live webcast of the presentation and Q&A session can be accessed on
the investor page of Sage's website at investor.sagerx.com. A replay of
the webcast will also be archived for up to 30 days on Sage's website
following the conference.
About Sage Therapeutics
Sage Therapeutics is a clinical-stage biopharmaceutical company
committed to developing novel medicines to transform the lives of
patients with life-altering central nervous system (CNS) disorders. Sage
has a portfolio of novel product candidates targeting critical CNS
receptor systems, GABA and NMDA. Sage's lead program, a proprietary IV
formulation of brexanolone (SAGE-547), has completed two Phase 3
clinical trials in postpartum depression. Sage is developing its next
generation modulators, including SAGE-217 and SAGE-718, in various CNS
disorders. For more information, please visit www.sagerx.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180102005782/en/
Source: Sage Therapeutics
Maureen L. Suda, 585-387-9248